$BMRN News Biotech comeback stalls as Wall Street

New Post Public Reply Private Reply Replies (0) Message Board

Jun 4, 2014 at 7:19 PM

$BMRN News

Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
Major U.S. benchmarks pull in to first support 12:27 p.m. March 10, 2014 - Michael Ashbaugh
BioMarin shares rally as FDA mutes criticism of rare disorder drug 6:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 12:10 p.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 6:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 11:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 1:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 3:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 5:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 12:56 p.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 1:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 12:39 p.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 1:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 12:17 p.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 12:49 p.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 7:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 10:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 10:46 a.m. Oct. 3, 2012 - Michael Ashbaugh

Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders 10:30 a.m. Today - TheStreet.com
Drugs Stocks On The Rise With Help From 3 Stocks 1:02 p.m. June 3, 2014 - TheStreet.com
BioMarin's Pipeline Advances - Analyst Blog 11:40 a.m. May 29, 2014 - Zacks.com
The Trader Daily 7:30 a.m. May 29, 2014 - RealMoney.com
A Tale of Diversification 2:00 p.m. May 19, 2014 - RealMoney.com
Top Biotech Stocks for Cancer Cures from Cowen 8:08 a.m. May 16, 2014 - 247WallSt.com
Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders 10:30 a.m. May 14, 2014 - TheStreet.com
'Mad Money' Lightning Round: BioMarin Is for Real 6:00 a.m. May 8, 2014 - TheStreet.com
Cramer's Lightning Round - BioMarin Is A Biotech Survivor (5/7/14) 4:29 a.m. May 8, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: A Market Divided 8:12 p.m. May 7, 2014 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – ARIA SGEN BMRN ARNA 8:45 a.m. May 5, 2014 - InvestorPlace.com
BioMarin Pharmaceutical Inc. (BMRN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. May 5, 2014 - Zacks.com
Loss at BioMarin Narrower Than Expected - Analyst Blog 4:00 p.m. May 2, 2014 - Zacks.com
10-Q: BIOMARIN PHARMACEUTICAL INC 12:18 p.m. May 2, 2014 - Edgar Online - (EDG = 10Q, 10K)
BioMarin Pharmaceutical's CEO Discusses Q1 2014 Results - Earnings Call Transcript 12:50 a.m. May 2, 2014 - Seeking Alpha
More on Biomarin Q1 results 5:18 p.m. May 1, 2014 - Seeking Alpha
Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock 4:27 p.m. May 1, 2014 - TheStreet.com
Notable earnings after Thursday close 5:35 p.m. April 30, 2014 - Seeking Alpha
EC approves Vimizim 11:48 a.m. April 28, 2014 - Seeking Alpha
Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases 8:48 a.m. April 23, 2014 - Seeking Alpha

Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease 8:02 a.m. May 27, 2014 - GlobeNewswire
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex 8:29 a.m. May 7, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma 9:15 a.m. May 6, 2014 - PR Newswire - PRF
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th 8:02 a.m. May 6, 2014 - GlobeNewswire
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress 4:06 p.m. May 1, 2014 - GlobeNewswire
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages 11:08 a.m. April 28, 2014 - GlobeNewswire
Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics 8:00 a.m. April 25, 2014 - PR Newswire - PRF
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET 8:02 a.m. April 16, 2014 - GlobeNewswire
Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma 11:15 a.m. April 15, 2014 - PR Newswire - PRF
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver 9:31 a.m. April 14, 2014 - PR Newswire - PRF
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets 8:02 a.m. April 14, 2014 - GlobeNewswire
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin 8:00 a.m. April 11, 2014 - PR Newswire - PRF
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma 11:55 a.m. March 26, 2014 - PR Newswire - PRF
BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors 8:01 a.m. March 21, 2014 - GlobeNewswire
Critical Alerts For Voxeljet, QUALCOMM, Canadian Solar, NQ Mobile, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. March 19, 2014 - PR Newswire - PRF
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update 8:16 a.m. March 19, 2014 - GlobeNewswire
BioMarin Announces Pricing of Public Offering of Common Stock 9:00 a.m. March 5, 2014 - GlobeNewswire
BioMarin Announces Public Offering of Common Stock 5:22 p.m. March 4, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...